EDGAR·FLOW

Coya Therapeutics, Inc. — Form 8-K

Filed November 10, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Coya completed enrollment of 137 participants (vs. 120 planned) in its Phase 2/3 ALSTARS trial of COYA 302 for ALS treatment. The company holds $35.8M cash as of Sept 30, 2026, sufficient to fund operations past the Q2 2027 topline readout into H2 2027. Q3 2026 net loss was $10.6M (vs. $2.1M in Q3 2025); R&D expenses rose $5.7M driven by clinical trial advancement.
Why this rating

Trial completion is material clinical milestone for $89M biotech; $35.8M cash runway covers key catalyst. Elevated Q3 burn rate concerning but expected during trial execution phase.

Tradability signal
NO TRADE

No trade: positive news with only -1.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.11% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$3.18
+10 min · unknown
$3.25 ▲ 2.36%
+30 min · unknown
$3.41 ▲ 7.23%
+1 hr · unknown
$3.41 ▲ 7.23%
+4 hrs · unknown
$3.21 ▲ 0.94%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ COYA · stock on Yahoo Finance ↗

See more from November 10, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.